Results 151 to 160 of about 87,758 (253)

Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer's disease biomarkers and drug response heterogeneity

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) exhibits high genetic and clinical heterogeneity that limits therapeutic success. Patient‐derived brain organoids and their extracellular vesicles (EVs) provide physiologically relevant models to study disease mechanisms and individualized drug responses.
Rachel J. Boyd, Daiyun Dong, Ram Sagar, Anton Iliuk, Waqar Ahmed, Xenia Androni, Anton P. Porsteinsson, Paul B. Rosenberg, Constantine G. Lyketsos, Kenneth W. Witwer, Vasiliki Mahairaki   +10 more
wiley   +1 more source

Cyclic alternating pattern in sleep electroencephalography as a novel predictor of dementia: A prospective study

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Cyclic alternating pattern (CAP) is a sleep physiological rhythm observed during non–rapid eye movement (NREM) stage. However, the potential role of CAP for risk of dementia remains unknown. METHODS We studied 2,557 participants enrolled in the prospective Osteoporotic Fractures in Men (MrOS) Sleep Study.
Ying Zheng, Xinyue Wu, Haizhen Chen, Fan Li, Kristine Yaffe, Katie Stone, Yue Leng, Xiao Tan   +7 more
wiley   +1 more source

Basal Forebrain Volume Predicts Disease Conversion in Prodromal Synucleinopathy. [PDF]

Mov Disord Clin Pract
Churchill L, Konuri A, Ignatavicius A, Anderson J, Lewis SJG, Matar E.   +5 more
europepmc   +1 more source

Impact of early locus coeruleus lesions in the TgF344 Alzheimer's disease rat model

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION In murine models of Alzheimer's disease (AD), lesioning the locus coeruleus–norepinephrine (LC‐NE) system with DSP‐4 exacerbates AD‐like neuropathology and cognitive impairment. However, the impact of LC lesions during prodromal stages is poorly characterized. METHODS TgF344‐AD and wild‐type rats received monthly injections of DSP‐
Alexia E. Marriott, Jason P. Schroeder, Anu Korukonda, Brittany S. Pate, Katharine E. McCann, David Weinshenker, Michael A. Kelberman   +6 more
wiley   +1 more source

Night‐to‐night rapid eye movement sleep variability: A relevant marker of early amyloid‐β deposition

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Sleep disturbances are prevalent in patients with Alzheimer's disease (AD) and may emerge before overt clinical symptoms. We characterized sleep alterations in cognitively unimpaired older adults with cerebral amyloid deposition, and assessed their associations with regional amyloid deposition and cognitive and psychoaffective ...
Blandine Montagne, Maéva Boulin, Anaïs Hamel, Pierre Champetier, Stéphane Rehel, Florence Mézenge, Brigitte Landeau, Marion Delarue, Oriane Hébert, Célia Soussi, Françoise Bertran, Gaël Chételat, Claire André, Géraldine Rauchs, the Medit‐Ageing Research Group   +14 more
wiley   +1 more source

Human iPSC‐derived GABAergic interneuron transplantation restores circuit balance and cognitive function in an Alzheimer's disease model

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by disrupted excitatory–inhibitory (E:I) balance and impaired synaptic function, yet current treatments fail to repair these fundamental circuit impairments. METHODS Human induced pluripotent stem cell‐derived post‐mitotic medial ganglionic eminence‐originated inhibitory neurons (MGE‐pINs)
Xinzhe Zhang, Gaojie Wang, Haodong Chen, Ye Sun, Ziteng Wangliu, Lijing Wang, Miao Sun, Qing Liu, Xue Zhang   +8 more
wiley   +1 more source

A Simple Three-Dimensional Compartmentalized Co-Culture Model for Basal Forebrain and Hippocampal Neurons. [PDF]

Biology (Basel)
Luo X, Li J, Deng Z, Xu Y, Li X, Ren M, Li X.   +6 more
europepmc   +1 more source

Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome.
Clíona Farrell, Fedal Saini, Mona M. Beidas, Natalie S. Ryan, Andre Strydom, Frances K. Wiseman   +5 more
wiley   +1 more source